Squarepoint
NVAX icon

Squarepoint’s Novavax NVAX Stock Holding History

Squarepoint’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-63,500
Closed -$427K – 4737
2025
Q4 		$427K Sell
63,500
-86,900
-58% -$655K ﹤0.01% 3337
2025
Q3 		$1.3M Hold
150,400
– – ﹤0.01% 2452
2025
Q2 		$948K Sell
150,400
-700
-0.5% -$4.63K ﹤0.01% 2708
2025
Q1 		$969K Sell
151,100
-174,900
-54% -$1.45M ﹤0.01% 2693
2024
Q4 		$2.62M Buy
326,000
+299,800
+1,144% +$2.89M ﹤0.01% 2182
2024
Q3 		$331K Buy
+26,200
New +$338K ﹤0.01% 3382
2022
Q1 		– Sell
-20,100
Closed -$2.88M – 3312
2021
Q4 		$2.88M Hold
20,100
– – 0.01% 1054
2021
Q3 		$4.17M Hold
20,100
– – 0.01% 863
2021
Q2 		$4.27M Buy
+20,100
New +$3.68M 0.02% 798

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's NVAX Position: Q3 2025 in Review

Squarepoint sold out of Novavax (NVAX) in Q3 2025, closing a stake of 79,652 shares — an estimated $620K sold.

Squarepoint first reported a position in NVAX in Q3 2015 and held it in 26 quarters. The position peaked at $11.6M in Q2 2022. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

  • Squarepoint reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 79,652 Novavax shares in Q3 2025, an estimated $620K.
  • Squarepoint first reported a position in Novavax in Q3 2015 and held it in 26 quarters.
  • Squarepoint's Novavax position peaked at $11.6M in Q2 2022.
  • 249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.